AAPL344.17-5.34 (-1.53%) ▼|ABBV288.24-6.59 (-2.24%) ▼|ABT113.60-1.91 (-1.65%) ▼|ACN265.16+0.89 (+0.34%) ▲|ADBE246.44-2.04 (-0.82%) ▼|AMAT319.25-50.15 (-13.58%) ▼|AMD404.40-84.38 (-17.26%) ▼|AMGN460.28-18.20 (-3.80%) ▼|AMT193.99-0.87 (-0.45%) ▼|AMZN260.21-5.82 (-2.19%) ▼|AVGO291.53-33.95 (-10.43%) ▼|AXP324.97-7.62 (-2.29%) ▼|BA172.50-4.50 (-2.54%) ▼|BAC49.76-1.87 (-3.62%) ▼|BKNG168.72-2.25 (-1.32%) ▼|BLK1,170.67-53.70 (-4.39%) ▼|BMY63.13-1.06 (-1.65%) ▼|BNY147.49-5.23 (-3.42%) ▼|BRK-B572.33-6.76 (-1.17%) ▼|C118.45-6.29 (-5.04%) ▼|CAT553.64-37.66 (-6.37%) ▼|CL98.69-0.07 (-0.07%) ▼|CMCSA24.95+0.10 (+0.40%) ▲|COF203.84-2.47 (-1.20%) ▼|COP135.46-1.48 (-1.08%) ▼|COST1,065.59+19.12 (+1.83%) ▲|CRM222.41-4.70 (-2.07%) ▼|CSCO95.72-7.89 (-7.62%) ▼|CVS81.33+1.37 (+1.71%) ▲|CVX212.93-4.03 (-1.86%) ▼|DE663.31-13.19 (-1.95%) ▼|DHR226.34-8.59 (-3.66%) ▼|DIS117.22-1.73 (-1.45%) ▼|DUK130.08+0.49 (+0.38%) ▲|EMR162.61-7.83 (-4.59%) ▼|FDX316.80-12.60 (-3.83%) ▼|GD356.35-8.52 (-2.34%) ▼|GE314.73-14.72 (-4.47%) ▼|GEV770.51-62.32 (-7.48%) ▼|GILD167.57-6.91 (-3.96%) ▼|GM89.33-3.10 (-3.35%) ▼|GOOG281.74-5.56 (-1.94%) ▼|GOOGL282.57-6.36 (-2.20%) ▼|GS868.95-59.05 (-6.36%) ▼|HD349.94-5.50 (-1.55%) ▼|HON215.78-12.69 (-5.55%) ▼|IBM247.11-7.21 (-2.84%) ▼|INTC52.25-6.02 (-10.33%) ▼|INTU354.84-1.80 (-0.50%) ▼|ISRG468.52-13.58 (-2.82%) ▼|JNJ272.32-4.00 (-1.45%) ▼|JPM337.34-14.77 (-4.19%) ▼|KO95.73-0.07 (-0.07%) ▼|LIN521.23-3.51 (-0.67%) ▼|LLY1,364.73-53.26 (-3.76%) ▼|LMT576.16-18.88 (-3.17%) ▼|LOW227.24-2.14 (-0.93%) ▼|LRCX185.20-36.23 (-16.36%) ▼|MA655.92-16.76 (-2.49%) ▼|MCD278.04-2.18 (-0.78%) ▼|MDLZ66.82-0.56 (-0.83%) ▼|MDT104.84-0.12 (-0.11%) ▼|META605.08-24.92 (-3.96%) ▼|MMM187.77-6.18 (-3.19%) ▼|MO77.58-0.43 (-0.55%) ▼|MRK146.94-3.42 (-2.27%) ▼|MS182.44-11.53 (-5.94%) ▼|MSFT535.93-19.87 (-3.58%) ▼|MU656.39-138.84 (-17.46%) ▼|NEE88.25-0.20 (-0.23%) ▼|NFLX65.56-0.83 (-1.25%) ▼|NKE39.56-0.93 (-2.30%) ▼|NOW102.36-6.45 (-5.93%) ▼|NVDA181.60-18.53 (-9.26%) ▼|ORCL115.16-8.57 (-6.93%) ▼|PEP142.71+0.29 (+0.20%) ▲|PFE29.88-0.91 (-2.96%) ▼|PG167.10-0.22 (-0.13%) ▼|PLTR154.99-16.71 (-9.73%) ▼|PM201.50-9.78 (-4.63%) ▼|QCOM156.75-16.44 (-9.49%) ▼|RTX191.88-6.55 (-3.30%) ▼|SBUX106.16-3.54 (-3.23%) ▼|SCHW92.58-0.79 (-0.85%) ▼|SO93.34+0.22 (+0.24%) ▲|SPG226.55-1.95 (-0.85%) ▼|T21.82-0.01 (-0.05%) ▼|TMO676.94-29.22 (-4.14%) ▼|TMUS160.59+1.42 (+0.89%) ▲|TSLA343.69-41.50 (-10.77%) ▼|TXN278.15-33.34 (-10.70%) ▼|UBER68.78-1.09 (-1.56%) ▼|UNH395.72-13.66 (-3.34%) ▼|UNP297.95-10.58 (-3.43%) ▼|UPS111.04-3.27 (-2.86%) ▼|USB59.75-1.28 (-2.10%) ▼|V422.59-13.98 (-3.20%) ▼|VZ46.12-0.05 (-0.11%) ▼|WFC84.80-2.63 (-3.01%) ▼|WMT127.72-1.45 (-1.12%) ▼|XOM165.30-3.97 (-2.35%) ▼|AAPL344.17-5.34 (-1.53%) ▼|ABBV288.24-6.59 (-2.24%) ▼|ABT113.60-1.91 (-1.65%) ▼|ACN265.16+0.89 (+0.34%) ▲|ADBE246.44-2.04 (-0.82%) ▼|AMAT319.25-50.15 (-13.58%) ▼|AMD404.40-84.38 (-17.26%) ▼|AMGN460.28-18.20 (-3.80%) ▼|AMT193.99-0.87 (-0.45%) ▼|AMZN260.21-5.82 (-2.19%) ▼|AVGO291.53-33.95 (-10.43%) ▼|AXP324.97-7.62 (-2.29%) ▼|BA172.50-4.50 (-2.54%) ▼|BAC49.76-1.87 (-3.62%) ▼|BKNG168.72-2.25 (-1.32%) ▼|BLK1,170.67-53.70 (-4.39%) ▼|BMY63.13-1.06 (-1.65%) ▼|BNY147.49-5.23 (-3.42%) ▼|BRK-B572.33-6.76 (-1.17%) ▼|C118.45-6.29 (-5.04%) ▼|CAT553.64-37.66 (-6.37%) ▼|CL98.69-0.07 (-0.07%) ▼|CMCSA24.95+0.10 (+0.40%) ▲|COF203.84-2.47 (-1.20%) ▼|COP135.46-1.48 (-1.08%) ▼|COST1,065.59+19.12 (+1.83%) ▲|CRM222.41-4.70 (-2.07%) ▼|CSCO95.72-7.89 (-7.62%) ▼|CVS81.33+1.37 (+1.71%) ▲|CVX212.93-4.03 (-1.86%) ▼|DE663.31-13.19 (-1.95%) ▼|DHR226.34-8.59 (-3.66%) ▼|DIS117.22-1.73 (-1.45%) ▼|DUK130.08+0.49 (+0.38%) ▲|EMR162.61-7.83 (-4.59%) ▼|FDX316.80-12.60 (-3.83%) ▼|GD356.35-8.52 (-2.34%) ▼|GE314.73-14.72 (-4.47%) ▼|GEV770.51-62.32 (-7.48%) ▼|GILD167.57-6.91 (-3.96%) ▼|GM89.33-3.10 (-3.35%) ▼|GOOG281.74-5.56 (-1.94%) ▼|GOOGL282.57-6.36 (-2.20%) ▼|GS868.95-59.05 (-6.36%) ▼|HD349.94-5.50 (-1.55%) ▼|HON215.78-12.69 (-5.55%) ▼|IBM247.11-7.21 (-2.84%) ▼|INTC52.25-6.02 (-10.33%) ▼|INTU354.84-1.80 (-0.50%) ▼|ISRG468.52-13.58 (-2.82%) ▼|JNJ272.32-4.00 (-1.45%) ▼|JPM337.34-14.77 (-4.19%) ▼|KO95.73-0.07 (-0.07%) ▼|LIN521.23-3.51 (-0.67%) ▼|LLY1,364.73-53.26 (-3.76%) ▼|LMT576.16-18.88 (-3.17%) ▼|LOW227.24-2.14 (-0.93%) ▼|LRCX185.20-36.23 (-16.36%) ▼|MA655.92-16.76 (-2.49%) ▼|MCD278.04-2.18 (-0.78%) ▼|MDLZ66.82-0.56 (-0.83%) ▼|MDT104.84-0.12 (-0.11%) ▼|META605.08-24.92 (-3.96%) ▼|MMM187.77-6.18 (-3.19%) ▼|MO77.58-0.43 (-0.55%) ▼|MRK146.94-3.42 (-2.27%) ▼|MS182.44-11.53 (-5.94%) ▼|MSFT535.93-19.87 (-3.58%) ▼|MU656.39-138.84 (-17.46%) ▼|NEE88.25-0.20 (-0.23%) ▼|NFLX65.56-0.83 (-1.25%) ▼|NKE39.56-0.93 (-2.30%) ▼|NOW102.36-6.45 (-5.93%) ▼|NVDA181.60-18.53 (-9.26%) ▼|ORCL115.16-8.57 (-6.93%) ▼|PEP142.71+0.29 (+0.20%) ▲|PFE29.88-0.91 (-2.96%) ▼|PG167.10-0.22 (-0.13%) ▼|PLTR154.99-16.71 (-9.73%) ▼|PM201.50-9.78 (-4.63%) ▼|QCOM156.75-16.44 (-9.49%) ▼|RTX191.88-6.55 (-3.30%) ▼|SBUX106.16-3.54 (-3.23%) ▼|SCHW92.58-0.79 (-0.85%) ▼|SO93.34+0.22 (+0.24%) ▲|SPG226.55-1.95 (-0.85%) ▼|T21.82-0.01 (-0.05%) ▼|TMO676.94-29.22 (-4.14%) ▼|TMUS160.59+1.42 (+0.89%) ▲|TSLA343.69-41.50 (-10.77%) ▼|TXN278.15-33.34 (-10.70%) ▼|UBER68.78-1.09 (-1.56%) ▼|UNH395.72-13.66 (-3.34%) ▼|UNP297.95-10.58 (-3.43%) ▼|UPS111.04-3.27 (-2.86%) ▼|USB59.75-1.28 (-2.10%) ▼|V422.59-13.98 (-3.20%) ▼|VZ46.12-0.05 (-0.11%) ▼|WFC84.80-2.63 (-3.01%) ▼|WMT127.72-1.45 (-1.12%) ▼|XOM165.30-3.97 (-2.35%) ▼|
21 C
New York
Friday, November 6, 2026

Tag: Regulatory

newsFORsourcecompanycontentinformationreleases1market

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

NG ENERGY PROVIDES OPERATIONAL UPDATE

Sinu-9 currently producing over 12 MMcf/d, expected to increase to a minimum of 15 MMcf/d in early July 2025 Expansion of processing and compression...

Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

 – Broad label inclusive of all ages and disease severities –  – Launch to be initiated in Germany – WARREN, N.J., June 23, 2025 /PRNewswire/ -- PTC Therapeutics, Inc....

VIZSLA SILVER ANNOUNCES US$100 MILLION BOUGHT DEAL FINANCING

The offering documentation is or will be accessible through SEDAR+ and EDGAR VANCOUVER, BC, June 23, 2025 /PRNewswire/ - Vizsla Silver Corp. (TSX: VZLA) (NYSE:...

VIZSLA SILVER ANNOUNCES US$100 MILLION BOUGHT DEAL FINANCING

The offering documentation is or will be accessible through SEDAR+ and EDGAR VANCOUVER, BC, June 23, 2025 /CNW/ - Vizsla Silver Corp. (TSX: VZLA) (NYSE:...

Given Almost $75 Million in Executed Preferred Stock Purchase Agreements, Hyperscale Data Does Not Currently Intend to Raise Additional Equity

Agreements with Ault & Company and an Institutional Investor to Provide Capital Are Anticipated to Support Michigan Data Center Build-Out 
Agreements with Ault & Company and an Institutional Investor to Provide Capital Are Anticipated to Support Michigan Data Center Build-Out

Hormel Foods Announces Elevation of John Ghingo to President; Jeffrey M. Ettinger to Serve as Interim Chief Executive Officer

Ghingo will join Hormel Foods' board of directorsEttinger's role to conclude after 15 months AUSTIN, Minn., June 23, 2025 /PRNewswire/ -- Hormel Foods Corporation (NYSE:...

Rock Tech Lithium Receives $388,074 in Funding from Ontario’s Critical Minerals Innovation Fund

/NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ Ontario's Critical Minerals Innovation Fund awards $388,074 to Rock Tech...

E-Invoicing Could Unlock $116 Billion for the U.S. Economy & $616 Billion Globally, Avalara Finds

New global research from Avalara and Cebr reveals the transformative power of electronic invoicing adoption in the U.S. and across five other major markets...

E-Invoicing Could Unlock Nearly £9 Billion for the UK Economy, Avalara Finds

New global research from Avalara and Cebr reveals the transformative power of electronic invoicing adoption in the UK and across five other major marketsProductivity...

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

WBBA Broadband Development Congress Shanghai 2025 | Smarter Infrastructure: Converging AI and Broadband

SHANGHAI, June 23, 2025 /PRNewswire/ -- The World Broadband Association (WBBA) successfully convened the 2025 Broadband Development Congress in Shanghai, spotlighting the theme: "Smarter...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRegulatory

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers